<DOC>
	<DOCNO>NCT00655395</DOCNO>
	<brief_summary>- The purpose Phase I portion study evaluate safety combination medication determine appropriate dose VNP40101M use combination infusional cytarabine ( araC ) elderly patient Acute Myeloid Leukemia ( AML ) High Risk Myelodysplastic Syndrome ( MDS ) . - The purpose Phase II portion study evaluate effectiveness ( overall response rate ) patient treat VNP40101M infusional cytarabine induction therapy .</brief_summary>
	<brief_title>Treatment Elderly Patients With Acute Myeloid Leukemia ( AML ) High Risk Myelodysplastic ( MD ) Syndrome With Laromustine Infusional Cytarabine</brief_title>
	<detailed_description>There know standard chemotherapy consider effective old patient AML high risk MDS time , current treatment , tumor reduction difficult achieve short-lived . We , therefore , interested develop new drug might longer-lasting effect disease . Laromustine new drug show anti-cancer activity animal human study . It interact DNA cancer cell kill cell . Cytarabine ( AraC ) commercially available chemotherapy drug active leukemia use routinely disease first diagnose . In previous study , high dos laromustine give , laromustine AraC achieve response patient treat AraC alone . However , advantage offset fact patient give laromustine/AraC die due side effect . We wish determine effectiveness laromustine combination infusional AraC AML high risk MDS patient 60 year age .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<criteria>Diagnosis AML base WHO criterion ( great 20 % blast bone marrow blood ) exclude AML M3 , acute promyelocytic leukemia OR diagnosis highrisk MDS define International Prognostic Scoring System INT2 . ECOG performance status equal 0 , 1 , 2 . No prior treatment AML myeloablative treatment . Patients may prior treatment biologic therapy . Patients MDS AML evolve MDS could receive prior lowdose cytotoxic therapy agent azacytidine lowdose Ara C. Ability sign Informed Consent accord institutional guideline . Patients must follow clinical laboratory value within 24 hour prior begin protocol treatment : ) serum creatinine less equal 2.0mg/dl . b ) total bilirubin less equal 2.0 mg/dl c ) ALT AST less equal 5 time upper limit normal . Uncontrolled active infection . Patients infection active treatment antibiotic whose infection control may enter study . Patients chronic hepatitis eligible . Active heart disease include myocardial infarction , symptomatic coronary artery disease , arrhythmias control medication uncontrolled congestive heart failure . Severe pulmonary disease control medication . Patients serum creatinine &gt; 2.0 , serum bilirubin &gt; 2.0 . ALT AST great 5 time upper limit normal . Patients bilirubin creatinine outside acceptable level consider eligible abnormality clearly leukemia relate discuss principal 's investigator prior enrollment . Patients concurrently receive standard investigational treatment leukemia exception hydroxyurea . Since formulation contain 30 % ethanol , patient treat Antabuse ( disulfiram ) exclude study . Patients APL ( 15 ; 17 ) Patients ECOG performance status 3 4 . Patients metronidazole ( Flagyl ) least 24 hour start laromustine .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>MDS</keyword>
</DOC>